Metformin Pharmacology in Human Cancers: A Proof of Principle Study

Status Terminated

Clinical Trial Summary

This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma concentrations of metformin.

Clinical Trial Description

To understand the variability in clinical results testing metformin as an anti-cancer agent, it is important to determine the concentrations of metformin that are achievable in tissue. Clinical effects of metformin develop gradually over several days of treatment. Steady-state plasma metformin concentrations are correlated with anti-hyperglycemic response. Thus, achieving steady-state concentrations in this study will allow accurate determination of the most representative concentrations of metformin in normal and cancerous tissues, as well as determine AMP-activated protein kinase (AMPK) signaling differences in these tissues. As tha Primary Objective is to determine the concentration of metformin in tumors, patients will be treated with metformin extended release (ER) (Glucophage® XR), starting at 750 milligrams (mg) oral (PO) once daily (QD) for 4 days, then escalating to 750 mg PO twice daily (BID) for 3-6 days prior to surgery. FDA prescribing information indicates that metformin reaches steady-state plasma concentrations within 24-48 hours after the start of dosing in humans; thus, the 7-to-10-day time frame of this study will allow sufficient time for metformin to reach steady-state plasma concentrations, in addition to time allotted for potential accumulation in tissues. Metformin concentrations will be measured using a validated liquid chromatography-mass spectrometry (LC-MS/MS) assay. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03477162
Study type	Interventional
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Terminated
Phase	Early Phase 1
Start date	May 15, 2018
Completion date	November 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02204761` - Proton Beam Re-Irradiation in Thoracic Cancers	N/A
Completed	`NCT03331588` - Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer	Phase 3
Not yet recruiting	`NCT05321615` - Feasibility and Safety of a Wireless Palpator	N/A
Completed	`NCT03226925` - Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies	N/A
Completed	`NCT03890640` - Ultrasound-assisted Thoracic Epidural Catheter Insertion	N/A
Not yet recruiting	`NCT03168048` - Oncologic Therapy Support Via Means of a Dedicated Mobile App	N/A
Completed	`NCT03903991` - Evaluation of the Reliability of Oesophageal Temperature in THOracic Surgery
Active, not recruiting	`NCT03413449` - A Prospective Study Frailty for Esophagectomy and Lung Resection in Thoracic Surgery
Recruiting	`NCT04209868` - Preoperative Paravertebral Block in Cancer Surgery of the Lung	Phase 2/Phase 3
Recruiting	`NCT03521986` - Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS	Phase 3